Pacira BioSciences, Inc. (PCRX): Completion of Acquisition or Disposition of Assets
Pacira BioSciences, Inc. (PCRX) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 November 17, 2026 To: Holders of Pacira BioSciences, Inc. 2.125% Convertible Senior Notes due 2029 (CUSIP: 695127AJ9) and Computershare Trust Company, National Association as Trustee, Paying Agent and Conversion Agent Corporate Trust Office 1505 Energy Park Drive St.
- Role
- target
- Counterparty
- Viatris Inc.
- Price per share
- $36.50
- Consideration
- cash
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The filing confirms transaction completion and specifies that, after the effective time, holders convert the 2.125% notes into cash only, not PCRX shares, using $36.50 as the reference last reported sale price.
Market read
Confirms deal completion and clarifies convertible-note conversion mechanics, which can drive deal-arb and credit-sensitive positioning.
What to watch
Traders should monitor the make-whole adjustment and the exact conversion-rate increase timing for notes surrendered during the make-whole fundamental change window.
Background
Pacira entered an Agreement and Plan of Merger with Viatris, with a tender offer launched Oct. 30, 2026 and consummated Nov. 17, 2026.
Ticker impact
Pacira’s 8-K says the Viatris tender offer closed Nov. 17, 2026, converting PCRX shares into the $36.50 cash merger consideration.
Likely support for PCRX around the $36.50 offer price as the market prices completion and noteholders adjust conversion expectations.
The filing is a primary SEC disclosure of transaction consummation and the post-merger conversion right change for PCRX’s 2.125% notes.
Market effects
Limited direct sector read-through; this is primarily a capital-structure and deal-arbitrage catalyst for the issuer.
No clear regional spillover beyond US biotech M&A/deal-arb flows.
Low; transaction is US-listed and the disclosure is focused on note conversion mechanics.
Counterpoint
The conversion-right change may increase selling pressure from noteholders who prefer cash conversion, partially offsetting deal-arb support.
Key entities
- issuerPacira BioSciences, Inc.
Subject of the 8-K; merger close triggers common stock change event and supplemental indenture for convertible notes.
- acquirerViatris Inc.
Parent in the merger agreement; commenced and consummated the tender offer to acquire all outstanding PCRX shares.
- acquisition vehiclePeach Purchaser Sub Inc.
Wholly owned subsidiary of Viatris that merged into Pacira as the surviving corporation.
- trusteeComputershare Trust Company, National Association
Trustee, paying agent, and conversion agent under the 2029 convertible notes indenture.


